Innovative therapeutic strategies in the treatment of brain metastases

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 2135-2174

  Caffo, Maria ^a   Barresi, Valeria ^a   Caruso, Gerardo ^a   Cutugno, Mariano ^a   La Fata, Giuseppe ^a   Venza, Mario ^a   Alafaci, Concetta ^a   Tomasello, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Angiogenesis; Blood brain barrier; Brain metastases; Cancer stem cells; MicroRNA; Targeted therapy

Indexed keywords

AFATINIB; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; DABRAFENIB; DACARBAZINE; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; LAPATINIB; LGX 818; METHOTREXATE; MICRORNA; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NAVELBINE; NERATINIB; PACLITAXEL; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB;

ADVANCED CANCER; BLOOD BRAIN BARRIER; BONE METASTASIS; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN SURGERY; BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; GAMMA KNIFE RADIOSURGERY; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CANCER; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; PROSTATE CANCER; PROTEINURIA; REVIEW; STEREOTACTIC RADIOSURGERY; TUMOR INVASION; TUMOR VASCULARIZATION; BRAIN NEOPLASMS; METABOLISM; METASTASIS; MORTALITY; SECONDARY;

BRAIN NEOPLASMS; HUMANS; NEOPLASM METASTASIS;

EID: 84878640218     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14012135     Document Type: Review

References (175)

1. Kyritsis, A.P.; Markoula, S.; Levin, V.A. A systematic approach to the management of patients with brain metastases of known or unknown primary site. Cancer Chemother. Pharmacol. 2012, 69, 1-13.
2. Fidler, I.J. The role of the organ microenvironment in brain metastasis. Semin. Cancer Biol. 2011, 21, 107-112.
3. Mehta, M.P.; Rodrigus, P.; Terhaard, C.H.; Rao, A.; Suh, J.; Roa, W.; Souhami, L.; Bezjak, A.; Leibenhaut, M.; Komaki, R.; et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J. Clin. Oncol. 2003, 21, 2529-2536.
4. Melisko, M.E.; Moore, D.H.; Sneed, P.K.; De Franco, J.; Rugo, H.S. Brain metastases in breast cancer: Clinical and pathologic characteristics associated with improvements in survival. J. Neurooncol. 2008, 88, 359-365.
5. Andrews, D.W.; Scott, C.B.; Sperduto, P.W.; Flanders, A.E.; Gaspar, L.E.; Schell, M.C.; Werner-Wasik, M.; Demas, W.; Ryu, J.; Bahary, J.P.; et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363, 1665-1672.
6. Sanghavi, S.N.; Miranpuri, S.S.; Chappell, R.; Buatti, J.M.; Sneed, P.K.; Suh, J.H.; Regine, W.F.; Weltman, E.; King, V.J.; Goetsch, S.J.; et al. Radiosurgery for patients with brain metastases: A multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51, 426-434.
7. Patchell, R.A.; Tibbs, P.A.; Walsh, J.W.; Dempsey, R.J.; Maruyama, Y.; Kryscio, R.J.; Markesbery, W.R.; Macdonald, J.S.; Young, B. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990, 322, 494-500.
8. Addeo, R.; De Rosa, C.; Faiola, V.; Leo, L.; Cennamo, G.; Montella, L.; Guarrasi, R.; Vincenzi, B.; Caraglia, M.; Del Prete, S. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008, 113, 2524-2531.
9. Atkins, M.B.; Sosman, J.A.; Agarwala, S.; Logan, T.; Clark, J.I.; Ernstoff, M.S.; Lawson, D.; Dutcher, J.P.; Weiss, G.; Curti, B.; et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma. Cancer 2008, 113, 2139-2145.
10. Verger, E.; Gil, M.; Yaya, R.; Vinolas, N.; Villà, S.; Pujol, T.; Quintò, L.; Graus, F. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 2005, 61, 185-191.
11. Wels, J.; Kaplan, R.N.; Rafii, S.; Lyden, D. Migratory neighbors and distant invaders: Tumor-associated niche cells. Genes Dev. 2008, 22, 559-574.
12. Chiang, A.C.; Massague, J. Molecular basis of metastasis. N. Engl. J. Med. 2008, 359, 2814-2823.
13. Nguyen, D.X.; Massague, J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007, 8, 341-352.
14. Minn, A.J.; Kang, Y.; Serganova, I.; Gupta, G.P.; Giri, D.D.; Doubrovin, M.; Ponomarev, V.; Gerald, W.; Blasberg, R.; Massagué, J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J. Clin. Invest. 2005, 115, 44-55.
15. Wang, J.; Loberg, R.; Taichman, R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev. 2006, 25, 573-587.
16. Bremnes, R.M.; Veve, R.; Hirsch, F.R.; Franklin, W.A. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 2002, 36, 115-124.
17. Felding-Habermann, B.; O'Toole, T.; Smith, J.; Fransvea, E.; Ruggeri, Z.M.; Ginsberg, M.H.; Hughes, P.E.; Pampori, N.; Shattil, S.J.; Saven, A.; et al. Integrin activation controls metastasis in human breast cancer. Proc. Natl. Acad. Sci. USA 2001, 98, 1853-1858.
18. Yoshimasu, T.; Sakurai, T.; Oura, S.; Hirai, I.; Tanino, H.; Kokawa, Y.; Naito, Y.; Okamura, Y.; Ota, I.; Tani, N.; et al. Increased expression of integrin alpha3beta1 in highly brain metastatic subclone of a human non-small cell lung cancer cell line. Cancer Sci. 2004, 95, 142-148.
19. Lorger, M.; Krueger, J.S.; O'Neal, M.; Staflin, K.; Felding-Habermann, B. Activation of tumor cell integrin ανβ3 controls angiogenesis and metastatic growth in the brain. Proc. Natl. Acad. Sci. USA 2009, 106, 10666-10671.
20. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2, 161-174.
21. Jaalinoja, J.; Herva, R.; Korpela, M.; Hoytya, M.; Turpeenniemi-Hujanen, T. Matrix metalloproteinase 2 (MMP-2) immunoreactive protein is associated with poor grade and survival in brain neoplasms. J. Neurooncol. 2000, 46, 81-90.
22. Arnold, S.M.; Young, A.B.; Munn, R.K.; Patchell, R.A.; Nanayakkara, N.; Markesbery, W.R. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin. Cancer Res. 1999, 5, 4028-4033.
23. Folkman, J. Angiogenesis: An organizing principle for drug discovery? Nat. Rev. Drug Discov. 2007, 6, 273-286.
24. Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473, 298-307.
25. Jain, R.K.; di Tomaso, E.; Duda, D.G.; Loeffler, J.S.; Sorensen, A.G.; Batchelor, T.T. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 2007, 8, 610-622.
26. Ricci-Vitiani, L.; Pallini, R.; Biffoni, M.; Todaro, M.; Invernici, G.; Cenci, T.; Maira. G.; Parati, E.A.; Stassi, G.; Larocca, L.M. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468, 824-828.
27. Soda, Y.; Marumoto, T.; Friedmann-Morvinski, D.; Soda, M.; Liu, F.; Michiue, H.; Pastorino, S.; Yang, M.; Hoffman, R.M.; Kesari, S.; et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc. Natl. Acad. Sci. USA 2011, 108, 4274-4280.
28. Kusters, B.; Leenders, W.P.; Wesseling, P.; Smits, D.; Verrijp, K.; Ruiter, D.J.; Peters, J.P.; van Der Kogel, A.J.; de Waal, R.M. Vascular endothelial growth factor-A(165) induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res. 2002, 62, 341-345.
29. Carbonell, W.S.; Ansorge, O.; Sibson, N.; Muschel, R. The bascular basement membrane as "soil" in brain metastasis. PLoS One 2009, 4, e5857.
30. Küsters, B.; deWaal, R.M.; Wesseling, P.; Verrijp, K.; Maass, C.; Heerschap, A.; Barentsz, J.O.; Sweep, F.; Ruiter, D.J.; Leenders, W.P. Differential effects of vascular endothelial growth factor-A isoforms in a mouse brain metastasis model of human melanoma. Cancer Res. 2003, 63, 5408-5413.
31. Kim, L.; Huang, S.; Lu, W.; Lev, D.C.; Price, J. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 2004, 21, 107-118.
32. Fidler, I.J.; Yano, S.; Zhang, R.D.; Fujimaki, T.; Bucana, C.D. The seed and soil hypothesis: Vascularisation and brain metastases. Lancet Oncol. 2002, 3, 53-57.
33. Barresi, V.; Cerasoli, S.; Vitarelli, E.; Tuccari, G. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol. 2007, 114, 147-156.
34. Barresi, V.; Reggiani-Bonetti, L.; Di Gregorio, C.; Ponz de Leon, M.; Barresi, G.; Vitarelli, E. Stage I colorectal carcinoma: Vascular endothelial growth factor (VEGF) immunohistochemical expression, microvessel density and their correlation with clinical outcome. Virchows Arch. 2010, 457, 11-19.
35. Salgado, K.B.; Toscani, N.V.; Silva, L.L.; Hilbig, A.; Barbosa-Coutinho, L.M. Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: Evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas. Clin. Exp. Metastasis 2007, 24, 403-410.
36. Folberg, R.M.A. Vasculogenic mimicry. APMIS 2004, 112, 508-525.
37. Mihic-Probst, D.; Ikenberg, K.; Tinguely, M.; Schraml, P.; Behnke, S.; Seifert, B.; Civenni, G.; Sommer, L.; Moch, H.; Dummer, R. Tumor cell plasticity and angiogenesis in human melanomas. PLoS One 2012, 7, e33571.
38. Nathoo, N.; Chahlavi, A.; Barnett, G.H.; Toms, S.A. Pathobiology of brain metastases. J. Clin. Pathol. 2005, 58, 237-342.
39. Steeg, P. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer 2003, 3, 55-63.
40. De Marzo, A.M.; Knudsen, B.; Chan-Tack, K.; Epstein, J.I. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 1999, 53, 707-713.
41. Yaguchi, H.; Ohkura, N.; Tsukada, T.; Yamaguchi, K. Menin, the multiple endocrine neoplasia type 1 gene product, exhibits GTP-hydrolyzing activity in the presence of the tumor metastasis suppressor Nm23. J. Biol. Chem. 2002, 277, 38197-38204.
42. Fournier, H.N.; Albiges-Rizo, C.; Block, M.R. New insights into Nm23 control of cell adhesion and migration. J. Bioenerg. Biomembr. 2003, 35, 81-87.
43. Yoshida, B.A.; Dubauskas, Z.; Chekmareva, M.A.; Christiano, T.R., Stadler, W.M.; Rinker-Schaeffer, C.W. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res. 1999, 59, 5483-5487.
44. Gao, A.C.; Lou, W.; Sleeman, J.P.; Isaacs, J.T. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res. 1998, 58, 2350-2352.
45. Hori, A.; Honda, S.; Asada, M.; Ohtaki, T.; Oda, K.; Watanabe, T.; Shintani, Y.; Yamada, T.; Suenaga, M.; Kitada, C.; et al. Metastin suppresses the motility and growth of CHO cells transfected with its receptor. Biochem. Biophys. Res. Commun. 2001, 286, 958-963.
46. Samant, R.S.; Seraj, M.J.; Saunders, M.M.; Sakamaki, T.S.; Shevde, L.A.; Harms, J.F.; Leonard, T.O.; Goldberg, S.F.; Budgeon, L.; Meehan, W.J.; et al. Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin. Exp. Metastasis 2000, 18, 683-693.
47. Gildea, J.J.; Seraj, M.J.; Oxford, G.; Harding, M.A.; Hampton, G.M.; Moskaluk, C.A.; Frierson, H.F.; Conaway, M.R.; Theodorescu, D. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res. 2002, 62, 6418-6423.
48. Tamura, M.; Gu, J.; Takino, T.; Yamada, K.M. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: Differential involvement of focal adhesion kinase and p130Cas. Cancer Res. 1999, 59, 442-449.
49. Hahn, M.; Wieland, I.; Koufaki, O.N.; Gorgens, H.; Sobottka, S.B.; Schackert, G.; Schackert, H.K. Genetic alterations of the tumor suppressor gene PTEN/MMAC1 in human brain metastases. Clin. Cancer Res. 1999, 5, 2431-2437.
50. McClatchey, A.; Saotome, I.; Mercer, K.; Crowley, D.; Gusella, J.; Bronson, R.; Jacks, T. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 1998, 12, 1121-1133.
51. Kirsch, D.G.; Kastan, M.B. Tumor-suppressor p53: Implications for tumor development and prognosis. J. Clin. Oncol. 1998, 16, 3158-3168.
52. Nguyen, D.X.; Chiang, A.C.; Zhang, X.H.; Kim, J.Y.; Kris, M.G.; Ladanyi, M.; Gerald, W.L.; Massaqué, J. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009, 138, 51-62.
53. Bos, P.D.; Zhang, X.H.; Nadal, C.; Shu, W.; Gomis, R.R.; Nguyen, D.X.; Minn, A.J.; van de Vijver, M.J.; Gerald, W.L.; Foekens, J.A.; et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459, 1005-1009.
54. Webb, C.; van de Woude, G. Methods in Enzymology; Balch, W., Der, C., Hall, A., Eds.; Academic Press: San Diego, CA, USA, 2001; Volume 333, pp. 318-329.
55. Bromberg, J.F. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109, 1139-1142.
56. Chiu, W.T.; Lee, H.T.; Huang, F.J.; Aldape, K.D.; Yao, J.; Steeg, P.S.; Chou, C.Y.; Lu, Z.; Xie, K.; Huang, S. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by Stat3 inhibition. Cancer Res. 2011, 71, 493-443.
57. Xie, T.X.; Huang, F.J.; Aldape, K.D.; Kang, S.H.; Liu, M.; Gershenwald, J.E.; Xie, K.; Sawaya, R.; Huang, S. Activation of Stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006, 66, 3188-3196.
58. Kong, D.; Li, Y.; Wang, Z.; Sarkar, F.H. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel) 2011, 3, 716-729.
59. Ahmad, A.; Aboukameel, A.; Kong, D.; Wang, Z.; Sethi, S.; Chen, W.; Sarkar, F.H.; Raz, A. Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res. 2011, 71, 3400-3409.
60. Kahlert, C.; Lahes, S.; Radhakrishnan, P.; Dutta, S.; Mogler, C.; Herpel, E.; Brand, K.; Steinert, G.; Schneider, M.; Mollenhauer, M.; et al. Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitro. Clin. Cancer Res. 2011, 17, 7654-7663.
61. Nass, D.; Rosenwald, S.; Meiri, E.; Gilad, S.; Tabibian-Keissar, H.; Schlosberg, A.; Kuker, H.; Sion-Vardy, N.; Tobar, A.; Kharenko, O.; et al. MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2009, 19, 375-383.
62. Zhang, L.; Sullivan, P.S.; Goodman, J.C.; Gunaratne, P.H.; Marchetti, D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011, 71, 645-654.
63. Marchetti, D.; Nicolson, G. Human heparanase: A molecular determinant of brain metastasis. Adv. Enzyme Reg. 2001, 41, 343-359.
64. Li, X.; Pan, Y.Z.; Seigel, G.M.; Hu, Z.H.; Huang, M.; Yu, A.M. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328,-519c and-520h) and their differential expression in stem-like ABCG2{thorn} cancer cells. Biochem. Pharmacol. 2011, 81, 783-792.
65. Hwang, S.J.; Seol, H.J.; Park, Y.M.; Kim, H.K.; Gorospe, M.; Nam, D.H.; Kim, H.H. MicroRNA-146a suppresses metastatic activity in brain metastasis. Mol. Cells 2012, 34, 329-334.
66. Li, W.Q.; Li, Y.M.; Tao, B.B.; Lu, Y.C.; Hu, G.H.; Liu, H.M.; He, J.; Xu, Y.; Yu, H.Y. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med. Sci. Monit. 2010, 16, HY27-HY30.
67. Arora, S.; Ranade, A.R.; Tran, N.L.; Nasser, S.; Sridhar, S.; Korn, R.L.; Ross, J.T.; Dhruv, H.; Foss, K.M.; Sibenaller, Z.; et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int. J. Cancer 2011, 129, 2621-2631.
68. Feller, L.; Bouckaert, M.; Chikte, U.M.; Wood, N.H.; Khammissa, R.A.; Meyerov, R.; Lemmer, J. A short account of cancer-specifically in relation to squamous cell carcinoma. SADJ 2010, 65, 322-324.
69. Wicha, M.S.; Liu, S.; Dontu, G. Cancer stem cells: An old idea-a paradigm shift. Cancer Res. 2006, 66, 1883-1890.
70. Croker, A.K.; Allan, A.L. Cancer stem cells: Implications for the progression and treatment of metastatic disease. J. Cell. Mol. Med. 2008, 12, 374-390.
71. Kucia, M.; Reca, R.; Miekus, K.; Wanzeck, J.; Wojakowski, W.; Janowska-Wieczorek, A.; Ratajczak, J.; Ratajczak, M.Z. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23, 879-894.
72. Glass, D.A., II; Bialek, P.; Ahn, J.D.; Starbuck, M.; Patel, M.S.; Clevers, H.; Taketo, M.M.; Long, F.; McMahon, A.P.; Lang, R.A.; et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 2005, 8, 751-764.
73. Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715.
74. Pommier, S.J.; Quan, G. G,.; Christante, D.; Muller, P.; Newell, A.E.H.; Olson, S.B.; Diggs, B.; Muldoon, L.; Neuwelt, E.; Pommier, R.F. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. Ann. Surg. Oncol. 2010, 17, 613-623.
75. Guo, L.; Fan, D.; Zhang, F.; Price, J.E.; Lee, J.S.; Marchetti, D.; Fidler, I.J.; Langley, R.R. Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar. Am. J. Pathol. 2011, 178, 2357-2366.
76. Wang, C.; Natsume, A.; Lee, H.J.; Motomura, K.; Ohno, M.; Ito, M.; Kinjo, S.; Momota, H.; Iwami, K.; Ohka, F.; et al. Neural stem cell-based dual suicide gene delivery for metastatic brain tumors. Cancer Gene Ther. 2012, 19, 796-801.
77. Aboody, K.S.; Najbauer, J.; Schmidt, N.O.; Yang, W.; Wu, J.K.; Zhuge, Y.; Przylecki, W.; Carroll, R.; Black, P.M.; Perides, G. Targeting of melanoma brain metastases using engineered neural stem/progenitor cells. Neuro-Oncology 2006, 8, 119-126.
78. Seol, H.J.; Jin, J.; Seong, D.H.; Joo, K.M.; Kang, W.; Yang, H.; Kim, J.; Shin, C.S.; Kim, Y.; Kim, K.H.; et al. Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer Letters 2011, 311, 152-159.
79. Glinsky, G.V.; Berezovska, O.; Glinskii, A.B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J. Clin. Invest. 2005, 115, 1503-1521.
80. Hoenerhoff, M.J.; Chu. I.; Barkan, D.; Liu, Z.; Datta, S.; Dimri, G.P.; Green, J.E. BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases. Oncogene 2009, 28, 3022-3032.
81. Nam, D.; Jeon, H.; Kim, S.; Kim, M.H.; Lee, M.S.; Kim, H.; Joo, K.M.; Lee, D.S.; Price, J.E.; Bang, S.I.; et al. Activation of notch signaling in a xenograft model of brain metastasis. Clin. Cancer Res. 2008, 14, 4059-4066.
82. McGowan, P.M.; Simedrea, C.; Ribot, E.J.; Foster, P.J.; Palmieri, D.; Steeg, P.S.; Allan, A.L.; Chambers, A.F. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol. Cancer Res. 2011, 9, 834-844.
83. Caruso, G.; Caffo, M.; Raudino, G.; Alafaci, C.; Salpietro, F.M.; Tomasello, F. Antisense oligonucleotides as innovative therapeutic strategy in the treatment of high-grade gliomas. Recent Pat. CNS Drug Discov. 2010, 5, 53-69.
84. Caruso, G., Caffo, M., Alafaci, C., Raudino, G., Cafarella, D., Lucerna, S.; Salpietro, F.M.; Tomasello, F. Could nanoparticles systems have a role in the treatment of cerebral gliomas? Nanomedicine 2011, 7, 744-752.
85. Caruso, G.; Raudino, G.; Caffo, M.; Alafaci, C.; Granata, F.; Lucerna, S.; Salpietro, F.M.; Tomasello, F. Nanotechnology platforms in diagnosis and treatments of primary brain tumors. Recent Pat. Nanotechn. 2010, 4, 119-122.
86. Cardoso, F.L.; Brites, D.; Brito, M.A. Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Res. Rev. 2010, 64, 328-363.
87. Uchino, H.; Kanai, Y.; Kim, K.; Wempe, M.F.; Chairoungdua, Y.; Morimoto, E.; Anders, M.W.; Endou, H. Transport of amino acid-related compounds mediated by L-type amino acid transporter1 (LAT1): Insights into the mechanisms of substrate recognition. Mol. Pharmacol. 2002, 61, 729-737.
88. Urquhart, B.L.; Kim, R.B. Blood-brain barrier transporters and response to CNS-active drugs. Eur. J. Clin. Pharmacol. 2009, 65, 1063-1070.
89. Kemper, E.M.; Boogerd, W.; Thuis, I.; Beijnen, J.H.; van Tellingen, O. Modulation of the blood-brain barrier in oncology: Therapeutic opportunities for the treatment of brain tumours? Cancer Treat. Rev. 2004, 30, 415-423.
90. Pardridge, W.M. Blood-brain barrier delivery. Drug Discov. Today 2007, 12, 54-61.
91. Boado, R.J.; Zhang, Y.; Pardridge, W.M. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 2007, 96, 381-391.
92. Moos, T.; Morgan, E.H. The metabolism of neuronal iron and its pathogenic role in neurological disease: Review. Ann. N. Y. Acad. Sci. 2004, 1012, 14-26.
93. Rapoport, N.; Marin, A.P.; Timoshin, A.A. Effect of a polymeric surfactant on electron transport in HL-60 cells. Arch. Biochem. Biophys. 2000, 384, 100-108.
94. Adenot, M.; Merida, P.; Lahana, R. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 2. Cationic peptide vectors for brain delivery. Chemotherapy 2007, 53, 73-76.
95. Bindal, R.K.; Sawaya, R.; Leavens, M.E.; Lee, J.J. Surgical treatment of multiple brain metastases. J. Neurosurg. 1993, 79, 210-216.
96. Iwadate, Y.; Namba, H.; Yamaura, A. Significance of surgical resection for the treatment of multiple brain metastases. Anticancer Res. 2000, 20, 573-577.
97. Marsh, J.C.; Gielda, B.T.; Herskovic, A.M.; Abrams, R.A. Cognitive sparing during the administration of whole brain radiotherapy and prophylactic cranial irradiation: Current concepts and approaches. J. Oncol. 2010, 2010, 198-208.
98. Li, J.; Bentzen, S.M.; Li, J.; Renschler, M.; Mehta, M.P. Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71, 64-70.
99. Welzel, G.; Fleckenstein, K.; Schaefer, J.; Hermann, B.; Kraus-Tiefenbacher, U.; Mai, S.K.; Wenz, F. Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72, 1311-1318.
100. Gaspar, L.E.; Mehta, M.P.; Patchell, R.A.; Burri, S.H.; Robinson, P.D.; Morris, R.E.; Ammirati, M.; Andrews, D.W.; Asher, A.L.; Cobbs, C.S.; et al. The role of whole brain radiation therapy in the management of newly diagnosed bain metastases: A systematic review and evidence-based clinical practice guideline. J. Neurooncol. 2010, 96, 17-32.
101. Hoegler, D. Radiotherapy for palliation of symptoms in incurable Cancer. Curr. Probl. Cancer 1997, 21, 129-183.
102. Sun, A.; Bae, K.; Gore, E.M.; Movsas, B.; Wong, S.J.; Meyers, C.A.; Bonner, J.A.; Schild, S.E.; Gaspar, L.E.; Bogart, J.A.; et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: Neurocognitive and quality-of-life analysis. J. Clin. Oncol. 2011, 29, 279-286.
103. Alexander, E.; Moriarty, T.M.; Davis, R.B.; Wen, P.Y.; Fine, H.A.; Black, P.M.; Kooy, H.M.; Loeffler, J.S. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J. Natl. Cancer Inst. 1995, 87, 34-40.
104. Chang, S.D.; Murphy, M.; Geis, P.; Martin, D.P.; Hancock, S.L.; Doty, J.R.; Adler, J.R., Jr. Clinical experience with image-guided robotic radiosurgery (the cyberknife) in the treatment of brain and spinal cord tumors. Neurol. Med. Chir. (Tokyo) 1998, 38, 780-783.
105. Wang, Z.; Yuan, Z.; Zhang, W.; You, J.; Wang, P. Brain metastasis treated with cyberknife. Chin. Med. J. 2009, 122, 1847-1850.
106. Boogerd, W.; Dalesio, O.; Bais, E.M.; van der Sande, J.J. Respone of brain metastases from breast cancer to systemic chemotherapy. Cancer 1992, 69, 972-980.
107. Ardizzoni, A.; Hansen, H.; Dombernowsky, P.; Gamucci, T.; Kaplan, S.; Postmus, P.; Giaccone, G.; Schaefer, B.; Wanders, J.; Verweij, J. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J. Clin. Oncol. 1997, 15, 2090-2096.
108. Wong, E.T.; Berkenblit, A. The role of topotecan in the treatment of brain metastases. Oncologist 2004, 9, 68-79.
109. Lorusso, V.; Galetta, D.; Giotta, F.; Rinaldi, A.; Romito, S.; Brunetti, C.; Silvestris, N.; Colucci, G. Topotecan in the treatment of brain metastases. A phase II study of GOIM (gruppo oncologico dell'italia meridionale). Anticancer Res. 2006, 26, 2259-2264.
110. Paul, M.J.; Summers Y, Calvert H.; Rustin, G.; Brampton, M.H.; Thatcher, N.; Middleton, M.R. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res. 2002, 12, 175-178.
111. Park, Y.H.; Park, M.J.; Ji, S.H.; Yi, S.Y.; Lim, D.H.; Nam, D.H.; Lee, J.I.; Park, W.; Choi, D.H.; Huh, S.J.; et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br. J. Cancer 2009, 100, 894-900.
112. Palmieri, D.; Bronder, J.; Herring, J.; Yoneda, T.; Weil, R.J.; Stark, A.M.; Kurek, R.; Vega-valle, E.; Feigenbaum, L.; Halverson, D. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007, 67, 4190-4198.
113. Nam, B.H.; Kim, S.Y.; Han, H.S.; Kwon, Y.; Lee, K.S.; Kim, T.H.; Ro, J. Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res. 2008, 10, R20.
114. Bartsch, R.; Rottenfusser, A.; Wenzel, C.; Dieckmann, K.; Pluschnig, U.; Altorjai, G.; Rudas, M.; Mader, R.M.; Poetter, R.; Zielinski, C.C.; et al. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J. Neurooncol. 2007, 85, 311-317.
115. Bria, E.; Cuppone, F.; Fornier, M.; Nisticò, C.; Carlini, P.; Milella, M.; Sperduti, I.; Terzoli, E.; Cognetti, F.; Giannarelli, D.; et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: The dark side of the moon? A meta-analysis of the randomised trials. Breast Cancer Res. Treat. 2008, 109, 231-239.
116. Braen, A.P.; Perron, J.; Tellier, P.; Catala, A.R.; Kolaitis, G.; Geng, W. A 4-week intrathecal toxicity and pharmacokinetic study with trastuzumab in cynomolgus monkeys. Int. J. Toxicol. 2010, 3, 259-267.
117. Gaspar, L.; Scott, C.; Rotman, M.; Asbell, S.; Phillips T.; Wasserman, T.; McKenna, W.G.; Byhardt, R. Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 1997, 37, 745-751.
118. Gril, B.; Palmieri, D.; Bronder, J.L.; Herring, J.M.; Vega-Valle, E.; Feigenbaum, L.; Liwher, D.J.; Steinberg, S.M.; Merino, M.J.; Rubin, S.D.; et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl. Cancer Inst. 2008, 100, 1092-1103.
119. Geyer, C.E.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C.G.; Pienkowski, T.; Jagiello-Gruzsfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; et al. Lapatinib plus capecitabine for HER-2-positive advanced breast cancer. N. Engl. J. Med. 2006, 355, 2733-2743.
120. Iwata, H.; Narabayashi, M.; Ito, Y.; Saji, S.; Fujiwara, Y.; Usami, S.; Katsura, K.; Sasaki, Y. A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: Subset analysis of Japanese patients. Int. J. Clin. Oncol. 2012, doi:10.1007/s10147-012-0444-2.
121. Lin, N.U.; Diéras, V.; Paul, D.; Lossignol, D.; Christodoulou, C.; Stemmler, H.J.; Roché, H.; Liu, M.C.; Greil, R.; Ciruelos, E.; et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 2009, 15, 1452-1459.
122. Burel-Vandenbons, F.; Ambrosetti, D.; Coutts, M.; Pedeutour, F. EGFR mutation in brain metastases of non-small cell lung carcinoma. J. Neurooncol. 2013, 111, 1-10.
123. Rosell, R.; Moran, T.; Queralt, C.; Porta, R.; Cardenal, F.; Camps, C.; Majem, M.; Lopez-Vivanco, G.; Isla, D.; Provencio, M.; et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 2009, 361, 958-967.
124. Ishida, A.; Kanoh, K.; Nishisaka, T.; Miyazu, Y.; Iwamoto, Y.; Kohno, N.; Miyazawa, T. Gefinitib as a first line of therapy in non-small cell lung cancer with brain metastases. Intern. Med. 2004, 43, 718-720.
125. Nishi, N.; Kawai, S.; Yonezawa, T.; Fujimoto, K.; Masui, K. Effect of gefitinib on brain metastases from non-small cell lung cancer. Two case reports. Neurol. Med. Chir. (Tokyo) 2006, 46, 504-507.
126. Tang, W.H.; Chen, J.H.; Ye, R.H.; Ho, C.L. Near total regression of diffuse brain metastases in adenocardcinoma of the lung with an EGFR exon 19 mutations: A case report and review of the literature. Case Rep. Oncol. 2011, 4, 445-451.
127. Masago, K.; Togashi, Y.; Fukudo, M.; Terada, T.; Irisa, K.; Sakamori, Y.; Fujita, S.; Kim, Y.H.; Mio, T.; Inui, K.; et al. Good clinical response to erlotinib in a non-small cell lung cancer patient harboring multiple brain metastases and a double active somatic epidermal growth factor gene mutation. Case Rep. Oncol. 2010, 3, 98-105.
128. Lai, C.S.; Boshoff, C.; Falzon, M.; Lee, S.M. Complete response to erlotinib treatment in brain metastases from recurrent NSCLC. Thorax 2006, 61, 91.
129. Ceresoli, G.L.; Cappuzzo, F.; Gregorc, V.; Bartolini, S.; Crinò, L.; Villa, E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: A prospective trial. Ann. Oncol. 2004, 15, 1042-1047.
130. Kim, J.E.; Lee, D.H.; Choi, Y.; Yoon, D.H.; Kim, S.W.; Suh, C.; Lee, J.S. Epidermal growth receptor tyrosine kinase inhibitors as a first-line therapy for non-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastases. Lung Cancer 2009, 65, 351-354.
131. Heon, S.; Yeap, B.Y.; Britt, G.J.; Costa, D.B.; Rabin, M.S.; Jackman, D.M.; Johnson, B.E. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefinitib or erlotinib. Clin. Cancer Res. 2010, 16, 5873-82.
132. Shimato, S.; Mitsudomi, T.; Kosaka, T.; Yatabe, Y.; Wakabayashi, T.; Mizuno, N.; Nakahara, N.; Hatano, H.; Natsume, A.; Ishii, D.; et al. EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib. Neuro Oncol. 2006, 8, 137-144.
133. Zeng, Y.D.; Zhang, L.; Liao, H.; Liang, Y.; Xu, F.; Liu, J.L.; Dinglin, X.X.; Chen, K. Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small cell lung cancer: A retrospective study. Asian Pac. J. Cancer Prev. 2012, 13, 909-914.
134. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Eng. J. Med. 2007, 356, 125-134.
135. Pouessel, D.; Culine, S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur. Urol. 2008, 53, 376-381.
136. Massard, C.; Zonierek, J.; Gross-Goupil, M.; Fizazi, K.; Szczylik, C.; Escudier. B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann. Oncol. 2010, 21, 1027-1031.
137. Walid, M.S.; Johnston, K.W. Successful treatment of a brain-metastatized renal cell carcinoma. Ger. Med. Sci. 2009, 7, doi:10.3205/000087.
138. Shen, Y.; Ruan, M.; Luo, Q.; Yu, Y.; Lu, H.; Zhu, R.; Chen, L. Brain metastasis from follicular thyroid carcinoma: Treatment with sorafenib. Thyroid 2012, 22, 856-860.
139. Tsao, H.; Zhang, X.; Fowlkes, K.; Haluska, F.G. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000, 60, 1800-1804.
140. Long, G.V.; Menzies, A.M.; Nagrial, A.M.; Haydu, L.E.; Hamilton, A.L.; Mann, G.J.; Hughes, T.M.; Thompson, J.F.; Scolyer, R.A.; Kefford, R.F. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 2011, 29, 1239-1246.
141. Jakob, J.A.; Bassett, R.L., Jr.; Ng, C.S.; Curry, J.L.; Joseph, R.W.; Alvarado, G.C.; Rohlfs, M.L.; Richard, J.; Gershenwald, J.E.; Kim, K.B.; et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118, 4014-4023.
142. Flaherty, K.T.; Schiller, J.; Schuchter, L.M.; Liu, G.; Tuveson, D.A.; Redlinger, M.; Lathia, C.; Xia, C.; Petrenciuc, O.; Hingorani, S.R.; et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin. Cancer Res. 2008, 14, 4836-4842.
143. Menzies, A.M.; Long, G.V.; Murali, R. Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des. Devel. Ther. 2012, 6, 391-405.
144. Bollag, G.; Hirth, P.; Tsai, J.; Zhang, J.; Ibrahim, P.N.; Cho, H.; Spevak, W.; Zhang, C.; Zhang, Y.; Habets, G.; et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467, 596-599.
145. Joseph, E.W.; Pratilas, C.A.; Poulikakos, P.I.; Tadi, M.; Wang, W.; Taylor, B.S.; Halilovic, E.; Persaud, Y.; Xing, F.; Viale, A.; et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 2010, 107, 14903-14908.
146. Chapman, P.B.; Hauschild, A.; Robert, C.; Haanen, J.B.; Ascierto, P.; Larhin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; et al. BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 2011, 364, 2507-2516.
147. Dummer, R.; Goldinger, S.; Turtschi, C.; Eggmann, N.; Michielin, O.; Mitchell, L.; Veronese, L.; Hilfiker, P.R.; Rinderknecht, J.D. Open-label pilot study of vemurafenib in previously Treated Metastatic Melanoma (mM) Patients (pts) with Symptomatic Brain Metastases (BM). Ann. Oncol. 2012. Available online: http://abstracts.webges.com/viewing/view.php?congress=esmo2012&congress_ id=370&publication_id=2720 (accessed on 10 January 2013).
148. Davies, M.A.; Liu, P.; McIntyre, S.; Kim, K.B.; Papadopoulos, N.; Hwu, W.J.; Hwu, P.; Bedikian, A. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011, 117, 1687-1696.
149. Carlino, M.S.; Fogarty, G.B.; Long, G.V. Treatment of melanoma brain metastases: A new paradigm. Cancer J. 2012, 18, 208-212.
150. Long, G.V.; Trefzer, U.; Davies, M.A.; Kefford, R.F.; Ascierto, P.A.; Chapman. P.B.; Puzanov, I.; Hauschild, A.; Robert, C.; Algazi, A.; et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol. 2012, 13, 1087-1095.
151. Gore, M.E.; Hariharan, S.; Porta, C.; Bracarda, S.; Hawkins, R.; Bjarnason, G.A.; Oudard, S.; Lee, S.H.; Carteni, G.; Nieto, A.; et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2011, 117, 501-509.
152. Novello, S.; Camps, C.; Grossi, F.; Mazieres, J.; Abrey, L.; Vernejoux, J.M.; Thall, A.; Patyna, S.; Usari, T.; Wang, Z.; et al. Phase II study of sunitinib in patients with non-small cell lung cancer and irradiated brain metastases. J. Thorac. Oncol. 2011, 6, 1260-1266.
153. Batchelor, T.T.; Sorensen, A.G.; di Tomaso, E.; Zhang, W.T.; Duda, D.G.; Cohen, K.S.; Kozak, K.R.; Cahill, D.P.; Chen, P.J.; Zhu, M.; et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11, 83-95.
154. JuanYin, J.; Zhang, L.; Munasinghe, J.; Linnoila, I.; Kelly, K. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res. 2010, 70, 8662-8673.
155. JuanYin, J; Tracy, K.; Zhang, L.; Munasinghe, J.; Shapiro, E.; Koretsky, A.; Kelly, K. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin. Exp. Metastasis 2009, 26, 403-414.
156. Sandler, A. Bevacizumab in non-small cell lung cancer. Clin. Cancer Res. 2007, 13, 4613-4616.
157. Besse, B.; Lasserre, S.F.; Compton, P.; Huang, J.; Augustus, S.; Rohr, U.P. Bevacizumab safety in patients with central nervous system metastases. Clin. Cancer Res. 2010, 16, 269-278.
158. Socinski, M.A.; Langer, C.J.; Huang, J.E.; Kolb, M.M.; Wang, L.; Akerley, W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J. Clin. Oncol. 2009, 27, 5255-5261.
159. De Braganca, K.C.; Janjigian, Y.Y.; Azzoli, C.G.; Kris, M.G.; Pietanza, M.C.; Nolan, C.P.; Omuro, A.M.; Omuro, A.M.; Holodny, A.I.; Lassman, A.B. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. J. Neurooncol. 2010, 100, 443-447.
160. Yamamoto, D.; Iwase, S.; Tsubota, Y.; Sueoka, N.; Yamamoto, C.; Kitamura, K.; Odagiri, H.; Nagumo, Y. Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan breast cancer research betwotk-07 trial. Onco. Targets Ther. 2012, 5, 185-189.
161. Zhao, H.; Cui, K.; Nie, F.; Wang, L.; Brandl, M.B.; Jin, G.; Li, F.; Mao, Y.; Xue, Z.; Rodriguez, A.; et al. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: An in vivo analysis in triple-negative breast cancer models. Breast Cancer Res. Treat. 2012, 131, 425-436.
162. Rades, D.; Nadrowitz, R.; Buchmann, I.; Hunold, P.; Noack, F.; Schild, S.E.; Meller, B. Radiolabeled cetuximab plus whole-brain irradiation (WBI) for the treatment of brain metastases from non-small cell lung cancer (NSCLC). Strahlenther Onkol. 2010, 186, 458-462.
163. Grǿnberg, B.H.; Ciuleanu, T.; Flotten, O.; Knuuttila, A.; Abel, E.; Langer, S.W.; Krejcy, K.; Leipa, A.M.; Munoz, M.; Hahka-Kemppinen, M.; et al. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer 2012, 78, 63-69.
164. Bhojani, M.S.; Van Dort, M.; Rehemtulla, A.; Ross, B.D. Targeted imaging and therapy of brain cancer using theranostic nanoparticles. Mol. Pharm. 2010, 7, 1921-1929.
165. Choi, M.R.; Stanton-Maxey, K.J.; Stanley, J.K.; Levin, C.S.; Bardhan R, Akin, D.; Badve, S.; Sturgis, J.; Robinson, J.P.; Bashir, R.; et al. A cellular trojan horse for delivery of therapeutics nanoparticles into tumors. Nano Lett. 2007, 7, 3759-3765.
166. Campoli, M.; Ferrone, S. HLA antigen changes in malignant cells: Epigenetic mechanisms and biologic significance. Oncogene 2008, 27, 5869-5885.
167. Cathro, H.; Smolkin, M.; Theodorescu, D.; Jo, V.Y.; Ferrone, S.; Frierson, H.F., Jr. Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol. Immunother. 2010, 59, 465-472.
168. Raffaghello, L.; Nozza, P.; Moranti, F.; Camoriano, M.; Wang, X.; Garrè, M.L.; Cama, A.; Basso, G.; Ferrone, S.; Gambini, C.; et al. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res. 2007, 67, 5471-5478.
169. Liu, Y.; Komohara, Y.; Domenick, N.; Ohno, M.; Ikeura, M.; Hamilton, R.L.; Horbinski, C.; Wang, X.; Ferrone, S.; Okada, H. Expression of antigen processing and presenting molecoles in brain metastasis of breast cancer. Cancer Immunol. Immunother. 2012, 61, 789-801.
170. Nagorsen, D.; Scheibenbogen, C.; Marincola, F.M.; Letsch, A.; Keilholz, U. Natural T cell immunity against cancer. Clin. Cancer Res. 2003, 9, 4296-4303.
171. Caffo, M.; Caruso, G.; Barresi, V.; Pimo, M.A.; Venza, M.; Alafaci, C.; Tomasello, F. Immunohistochemical study of CD68 and CR3/43 in astrocytic gliomas. J. Analyt. Oncol. 2012, 1, 42-49.
172. Swann, J.B.; Smyth, M.J. Immune surveillance of tumors. J. Clin. Invest. 2007, 117, 1137-1146.
173. Comin-Anduix, B.; Chodon, T.; Sazegar, H.; Matsunaga, D.; Mock, S.; Jalil, J.; Escuin-Ordinas, H.; Chmielowski, B.; Koya, R.C.; Ribas, A.; et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin. Cancer Res. 2010, 16, 6040-6048.
174. Boni, A.; Cogdill, A.P.; Dang, P.; Udayakumar, D.; Njauw, C.N.; Sloss, C.M.; Ferrone, C.R.; Flaherty, K.T.; Lawrence, D.P.; Fisher, D.E.; et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010, 70, 5213-5219.
175. Ascierto, P.A.; Simeone, E.; Giannarelli, D.; Grimaldi, A.M.; Romano, A.; Mozzillo, N. Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: A possible algorithm for clinical use. J. Transl. Med. 2012, 10, 107.